SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- China Petroleum & Chemical Corporation (HKG: 0386, "Sinopec") hosted a themed forum and a signing ceremony on November 4 at the 8th China International Import Expo (CIIE 2025). The Company signed purchasing contracts with 34 partners from 17 countries and regions, which totaled US$40.9 billion, including 24 products from 10 major categories, including crude oil, chemicals, equipment, materials, consumer goods and more. Since the first CIIE in 2018, Sinopec has signed orders exceeding a total of US$325 billion in eight sessions.
Centered on the theme Technology Driven, AI Empowered: The Future of Energy, the forum focused on digital intelligence, technological innovation, new materials R&D, supply chain resilience enhancement, and exploring deeper international energy cooperation.
Zhao Dong, vice chairman and president of Sinopec, delivered a speech at the forum, which was moderated by Li Yonglin, director and senior vice president of Sinopec. Niu Shuanwen, director and senior vice president of Sinopec, attended the event and signed agreements with international partners.
"Sinopec is firmly committed to its primary mission of promoting high‑quality development. While continuing to consolidate the industrial foundation leveraging technological strength, the group also adheres to the principle of 'digital intelligence empowerment' to activate new engines of value creation, striving to advance the energy and chemical industry toward greater sophistication, intelligence, and sustainability," remarked Zhao Dong.
He emphasized that Sinopec's development is inseparable from the long‑term trust and strong support of global partners. Looking ahead to China's 15th Five‑Year Plan period, Zhao Dong outlined Sinopec's goal to work with all parties to strengthen scientific and technological innovation, break developmental bottlenecks, and build new industry advantages.
Zhao Dong also called for joint efforts to accelerate the pace of digital intelligence empowerment, promote deep integration of next‑generation information technology with the energy and chemical industry, and stimulate new drivers for industrial upgrading. Zhao Dong said Sinopec will expand green and low‑carbon cooperation, advancing clean and efficient use of traditional energy in parallel with the large‑scale development of new energy, thereby creating a sustainable development blueprint and a bright future for the energy and chemical industry.
Senior executives from leading firms—Datuk Sazali Hamzah (EVP & CEO Downstream, Petronas Chemicals Group), Axel Lorenz (CEO, Process Automation, Siemens), Aravind Yarlagadda (SVP, Industrial Solutions, Baker Hughes), and Audun M. Martinsen (Partner and Head of Energy Service Research, Rystad Energy)—delivered keynote speeches.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Sinopec Signs Deals Worth US$40.9 Billion at CIIE 2025
- Participates in CPHI Milan 2026, Expanding Manufacturing AX Reach in Pharma
- Showcasing key solutions for factory design, production operations, and quality management using the theme "Autonomous Factory in Pharma"
SEOUL, South Korea and MILAN, Oct. 7, 2026 /PRNewswire/ -- LG CNS, a leading AI Transformation company in Korea, is expanding its manufacturing AX business with a showcase of pharma-specific smart factory technologies at CPHI Milan 2026, the world's largest pharmaceutical and biotech exhibition.
The Convention on Pharmaceutical Ingredients (CPHI) is a global pharma and biotech trade show held at various global venues throughout the year, including the United States, Europe, Asia, and the Middle East. The Milan show is CPHI's flagship event, drawing around 60,000 visitors and roughly 3,000 companies from more than 160 countries. It is widely regarded as the premier stage on which the latest technologies and trends of the global pharma and biotech industry converge. LG CNS is the only Korean company participating in the newly created "AI & Tech" zone this year.
The theme of LG CNS's booth is Autonomous Factory in Pharma and is designed around the introduction of three smart factory solutions connecting factory design, production operations, and quality management. Pharma and biotech companies building or expanding production facilities can adopt these solutions across the entire process, from factory construction through ongoing operations.
For the factory design stage, LG CNS presents Factova Worldworks, a digital twin-based virtual validation simulator that recreates the actual factory in a virtual space. It models the factory layout in 3D to review the optimal placement of pharmaceutical manufacturing equipment, the routes that workers will take within the planned factory, and the path along which raw materials are to be transferred. Pharmaceutical factories separate zones such as cleanrooms and production areas to prevent raw material contamination. Worker access permissions also differ by zone, so planning their routes carefully in advance is more essential than in general manufacturing factories.
Factova Control is a data standardization and equipment control solution for the production operations stage. It automatically converts process data such as raw material ID numbers and formulations into a unified format, unit, and notation so that every manufacturing step works from consistent data. This lets customers respond immediately when adding new equipment or changing process workflows. The solution also detects equipment anomalies and predicts failures, using AI to analyze electrical current, temperature, and vibration data in real time to flag early warning signs.
The quality management solution analyzes data such as production volume, raw material temperature changes, and equipment operation history to check for product quality issues. It also supports everything from root-cause investigations to follow-up actions when problems are identified. Notably, when it detects an anomaly midway through a process, it immediately calculates alternatives to resolve the issue and then applies them to the next production step, proactively preventing defective products.
An AI agent trained on quality data also drafts the Annual Product Quality Review (APQR). Pharma and biotech companies conduct annual quality reviews to comply with each country's Good Manufacturing Practice (GMP) regulations and document the results in the APQR. Previously, staff collected, analyzed, and verified the required data by hand, a process that could take months. LG CNS has automated the entire process with AI, cutting the time required by more than 90%.
"The manufacturing AX solutions we are showcasing at this exhibition are tailored to pharma so we can support our pharma and biotech customers with intelligent automation across the entire process, from factory design to quality management," said Eddie Jang, Head of the Chemical/Battery Division at LG CNS. "As a turnkey provider covering every area of manufacturing, we will continue to use our advanced solutions to address the challenges of developing pharmaceutical manufacturing sites, which demand high precision and strict quality standards, and help customers produce medicines in a more automated and efficient way."
About LG CNS
LG CNS is a leading Korean AX (AI Transformation) company that continues to pioneer various emerging technologies, including AI, robotics, cloud computing, data center, and smart engineering, encompassing smart factories and smart logistics, as well as digital marketing. The company also leads the market through innovative system integration (SI) and system management (SM) capabilities across finance, manufacturing, the public sector, and various other industries. For more information, please visit https://www.lgcns.com.
SEOUL, South Korea and MILAN, Oct. 7, 2026 /PRNewswire/ -- LG CNS, a leading AI Transformation company in Korea, is expanding its manufacturing AX business with a showcase of pharma-specific smart factory technologies at CPHI Milan 2026, the world's largest pharmaceutical and biotech exhibition.
The Convention on Pharmaceutical Ingredients (CPHI) is a global pharma and biotech trade show held at various global venues throughout the year, including the United States, Europe, Asia, and the Middle East. The Milan show is CPHI's flagship event, drawing around 60,000 visitors and roughly 3,000 companies from more than 160 countries. It is widely regarded as the premier stage on which the latest technologies and trends of the global pharma and biotech industry converge. LG CNS is the only Korean company participating in the newly created "AI & Tech" zone this year.
The theme of LG CNS's booth is Autonomous Factory in Pharma and is designed around the introduction of three smart factory solutions connecting factory design, production operations, and quality management. Pharma and biotech companies building or expanding production facilities can adopt these solutions across the entire process, from factory construction through ongoing operations.
For the factory design stage, LG CNS presents Factova Worldworks, a digital twin-based virtual validation simulator that recreates the actual factory in a virtual space. It models the factory layout in 3D to review the optimal placement of pharmaceutical manufacturing equipment, the routes that workers will take within the planned factory, and the path along which raw materials are to be transferred. Pharmaceutical factories separate zones such as cleanrooms and production areas to prevent raw material contamination. Worker access permissions also differ by zone, so planning their routes carefully in advance is more essential than in general manufacturing factories.
Factova Control is a data standardization and equipment control solution for the production operations stage. It automatically converts process data such as raw material ID numbers and formulations into a unified format, unit, and notation so that every manufacturing step works from consistent data. This lets customers respond immediately when adding new equipment or changing process workflows. The solution also detects equipment anomalies and predicts failures, using AI to analyze electrical current, temperature, and vibration data in real time to flag early warning signs.
The quality management solution analyzes data such as production volume, raw material temperature changes, and equipment operation history to check for product quality issues. It also supports everything from root-cause investigations to follow-up actions when problems are identified. Notably, when it detects an anomaly midway through a process, it immediately calculates alternatives to resolve the issue and then applies them to the next production step, proactively preventing defective products.
An AI agent trained on quality data also drafts the Annual Product Quality Review (APQR). Pharma and biotech companies conduct annual quality reviews to comply with each country's Good Manufacturing Practice (GMP) regulations and document the results in the APQR. Previously, staff collected, analyzed, and verified the required data by hand, a process that could take months. LG CNS has automated the entire process with AI, cutting the time required by more than 90%.
"The manufacturing AX solutions we are showcasing at this exhibition are tailored to pharma so we can support our pharma and biotech customers with intelligent automation across the entire process, from factory design to quality management," said Eddie Jang, Head of the Chemical/Battery Division at LG CNS. "As a turnkey provider covering every area of manufacturing, we will continue to use our advanced solutions to address the challenges of developing pharmaceutical manufacturing sites, which demand high precision and strict quality standards, and help customers produce medicines in a more automated and efficient way."
About LG CNS
LG CNS is a leading Korean AX (AI Transformation) company that continues to pioneer various emerging technologies, including AI, robotics, cloud computing, data center, and smart engineering, encompassing smart factories and smart logistics, as well as digital marketing. The company also leads the market through innovative system integration (SI) and system management (SM) capabilities across finance, manufacturing, the public sector, and various other industries. For more information, please visit https://www.lgcns.com.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
LG CNS Showcases Pharma-Specific Manufacturing AX at World's Largest Pharma-Biotech Show
